Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody therapeutics - WuXi Biologics

Drug Profile

Research programme: antibody therapeutics - WuXi Biologics

Alternative Names: Neutralizing antibodies for 2019-nCoV - WuXi Biologics; Neutralizing antibodies for Coronavirus - WuXi Biologics

Latest Information Update: 03 Feb 2020

At a glance

  • Originator WuXi Biologics
  • Class Antibodies; Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 28 Jan 2020 Early research in COVID-2019-infections in China (Parenteral)
  • 28 Jan 2020 WuXi Biologics plans a clinical trial for COVID-2019-infections
  • 28 Jan 2020 WuXi Biologics plans preclinical toxicology studies for COVID-2019-infections

Development Overview

Introduction

Neutralising antibody therapeutics are being developed by WuXi Biologics for the treatment of COVID-2019 infections. WuXi Biologics is using is proprietary integrated technology platforms to develop these candidates. Early research is underway in China.

Key Development Milestones

In January 2020, WuXi Biologics announced its intention to produce the first batch of antibodies for preclinical toxicology studies and initial human clinical studies in two months. The company also plans to complete all studies from DNA to IND within 4-5 months [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antibodies, Antivirals
  • Mechanism of Action Undefined mechanism
  • WHO ATC code

    J05 (Antivirals for Systemic Use)

  • EPhMRA code

    J5 (Antivirals for Systemic Use)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research China Parenteral / unspecified WuXi Biologics 28 Jan 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
WuXi Biologics Originator China
WuXi Biologics Owner China

Development History

Event Date Update Type Comment
28 Jan 2020 Phase Change Early research in COVID-2019-infections in China (Parenteral) [1] Updated 03 Feb 2020
28 Jan 2020 Trial Update WuXi Biologics plans a clinical trial for COVID-2019-infections [1] Updated 03 Feb 2020
28 Jan 2020 Trial Update WuXi Biologics plans preclinical toxicology studies for COVID-2019-infections [1] Updated 03 Feb 2020

References

  1. WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus.

    Media Release
Back to top